Average first day pops ranged from -41% to +41% as nine deals raised a combined $2.1 billion this week. High-end software provider Altair was the top performer, returning 41% on its market debut, as investors valued its sticky customer base and...read more
Spero Therapeutics, which is developing treatments for drug-resistant bacterial infections, raised $77 million by offering 5.5 million shares at $14, the low end of the range of $14 to $16. It had previously filed to offer 5.0 million shares. Insiders indicated ...read more
The IPO market's active fourth quarter continues with another busy week. As many as nine IPOs plan to raise $2.1 billion. This week features three growth IPOs, all with positive operating income: toy maker Funko (FNKO), chip producer Aquantia (AQ) and...read more
Spero Therapeutics, which is developing antibiotics for drug-resistant bacterial infections, announced terms for its IPO on Monday. The Cambridge, MA-based company plans to raise $75 million by offering 5 million shares at a price range of $14 to $16....read more
US IPO Weekly Recap: No Pop! for Funko in 9 IPO week
Average first day pops ranged from -41% to +41% as nine deals raised a combined $2.1 billion this week. High-end software provider Altair was the top performer, returning 41% on its market debut, as investors valued its sticky customer base and...read more
Antibiotic biotech Spero Therapeutics prices IPO at $14 low end
Spero Therapeutics, which is developing treatments for drug-resistant bacterial infections, raised $77 million by offering 5.5 million shares at $14, the low end of the range of $14 to $16. It had previously filed to offer 5.0 million shares. Insiders indicated ...read more
US IPO Week Ahead: Bobbleheads, biotechs, software and more in a 9-IPO week
The IPO market's active fourth quarter continues with another busy week. As many as nine IPOs plan to raise $2.1 billion. This week features three growth IPOs, all with positive operating income: toy maker Funko (FNKO), chip producer Aquantia (AQ) and...read more
Antibiotic biotech Spero Therapeutics sets terms for $75 million IPO
Spero Therapeutics, which is developing antibiotics for drug-resistant bacterial infections, announced terms for its IPO on Monday. The Cambridge, MA-based company plans to raise $75 million by offering 5 million shares at a price range of $14 to $16....read more